Will the malaria vaccine be accepted in Pakistan after the experience of Covid-19 experience? Authors Hamza Nauman Fourth Year MBBS Student, Dow University of Health Sciences, Karachi, Pakistan Aabia Zakai Fourth Year MBBS Student, Dow University of Health Sciences, Karachi, Pakistan Anusha Anwer Fourth Year MBBS Student, Dow University of Health Sciences, Karachi, Pakistan DOI: https://doi.org/10.47391/JPMA.6910 Abstract Malaria, caused by Plasmodium species is transmitted by a female Anopheles mosquito. It is the second highest ranking reported disease in the public sectors in Pakistan infecting 4 million people annually.1 The struggle for a vaccine providing protection against malaria finally was successful when WHO recommended widespread usage of the newly developed RTS,S/AS01 (RTS,S) malaria vaccine for children at risk. The vaccine’s efficacy against all clinical episodes of malaria was 51% for children in the age range of 5–17 months after a year following the first 3 doses.2 ---Continue Downloads Full Text Article Published 2022-10-15 How to Cite Hamza Nauman, Zakai, A., & Anusha Anwer. (2022). Will the malaria vaccine be accepted in Pakistan after the experience of Covid-19 experience?. Journal of the Pakistan Medical Association, 72(11), 2371–2371. https://doi.org/10.47391/JPMA.6910 More Citation Formats ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver Download Citation Endnote/Zotero/Mendeley (RIS) BibTeX Issue Vol. 72 No. 11 (2022): NOVEMBER Section LETTER TO THE EDITOR